Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy

Archives of Dermatology

Volumn 141, Issue 3, 2005, Pages 305-311

  Querfeld, Christiane ^a   Rosen, Steven T ^a   Kuzel, Timothy M ^a   Kirby, Katharine A ^a   Roenigk Jr , Henry H ^a   Prinz, Bettina M ^a   Guitart, Joan ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOXSALEN; PSORALEN;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CORNEA DISEASE; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; EARLY CANCER; ELASTOSIS; ERYTHEMA; EVALUATION; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEALTH CENTER; HUMAN; KAPLAN MEIER METHOD; KERATOSIS; LENTIGO; LICHENOID; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MONOTHERAPY; MYCOSIS FUNGOIDES; NAUSEA; NEVUS; OUTCOMES RESEARCH; PHOTOAGING; PHOTODERMATOSIS; PRIORITY JOURNAL; PRURITUS; PUVA; RADIATION INJURY; RETROSPECTIVE STUDY; SKIN CANCER; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TELANGIECTASIA; ULTRAVIOLET A RADIATION; XEROSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; PUVA THERAPY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 14944378170     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.141.3.305     Document Type: Article

References (42)

1. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354-371.
2. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health. 1999;89:1240-1244.
3. Querfeld C, Rosen ST, Kuzel TM, Guitart J. Cutaneous T-cell lymphomas: a review with emphasis on new treatment approaches. Semin Cutan Med Surg. 2003;22:150-161.
4. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis. Arch Dermatol. 1996;132:1309-1313.
5. Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol. 1999;135:26-32.
6. Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and long wave ultraviolet light. N Engl J Med. 1974;291:1207-1211.
7. Gilchrest BA, Parish JA, Tanenbaum L, Haynes HA, Fitzpatrick TB. Oral methoxypsoralen photochemotherapy of mycosis fungoides. Cancer. 1976;38:683-689.
8. Oguz O, Engin B, Aydemir EH. The influence of psoralen + ultraviolet A treatment on the duration of remission and prognosis in mycosis fungoides. J Eur Acad Dermatol Venereol. 2003;17:483-485.
9. Roupe G, Sandstrom MH, Kjellstrom C. PUVA in early mycosis fungoides may give long-term remission and delay extracutaneous spread. Acta Derm Venereol. 1996;76:475-478,
10. Herrmann JJ, Roenigk HH, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol. 1995;33:234-242.
11. Hönigsmann H, Brenner W, Rauschmeier W, et al. Photochemotherapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1984;10:238-245.
12. Molin L, Thomsen K, Volden G, Groth O. Photochemotherapy (PUVA) in the pretumor stage of mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Study Group. Acta Derm Venereol. 1981;61:47-51.
13. Briffa DV, Warin AP, Harrington CI, Bleehen SS. Photochemotherapy in mycosis fungoides: a study of 73 patients. Lancet. 1980;2:49-53.
14. Lowe NJ, Cripps DJ, Dufton PA, Vickers CF. Photochemotherapy for mycosis fungoides: a clinical and histological study. Arch Dermatol. 1979;115:50-53.
15. Kuzel TM, Roenigk HH, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with photochemotherapy for mycosis fungoides and Sézary syndrome. J Clin Oncol. 1995;13:257-263.
16. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood. 1998;92:3578-3581.
17. Chiarion-Sileni V, Bononi A, Fornasa CV, et al. Phase II trial of interteron-α-2a plus psoralen with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer. 2002;95:569-575.
18. Stern RS, Bolshakov S, Nataraj AJ, et al. p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet A-treated patients: evidence for heterogeneity and field cancerization. J Invest Dermatol. 2002;119:522-526.
19. Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol. 2003;121:252-258.
20. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA): the PUVA Follow-up Study. N Engl J Med. 1997;336:1041-1045.
21. Hannuksela-Svahn A, Pukkala E, Koulu L, et al. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA. J Am Acad Dermatol. 1999;40:694-696.
22. Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol. 1999;135:1377-1380.
23. Gathers RC, Scherschun L, Malick F, et al. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol. 2002;47:191-197.
24. Diederen PV, van Weelden H, Sanders CJ, et al. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol. 2003;48:215-219.
25. Plettenberg H, Stege H, Megahed M, et al. Ultraviolet A1 (340-400nm) phototherapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1999;41:47-50.
26. Bunn PA, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep. 1979;63:725-728.
27. Lynch WS, Roenigk HH Jr. Essentials for PUVA therapy: guidelines for photochemotherapy. Cutis. 1977;20:494-501.
28. Rosenbaum MM, Roenigk HH Jr, Caro WA, Esker A. Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaques: long-term follow-up in forty-three patients. J Am Acad Dermatol. 1985;13:613-622.
29. Poszepczynska-Guigne E, Bagot M, Wechsler J, et al. Minimal residual disease in mycosis fungoides follow-up can be assessed by polymerase chain reaction. Br J Dermatol. 2003:148:265-271.
30. Fraser-Andrews EA, Woolford AJ, Russell-Jones R, et al. Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol. 2000;114:117-121.
31. Delfau-Larue MH, Laroche L, Wechsler J, et al. Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood. 2000;96:2987-2992.
32. Yoo EK, Rook AH, Elenitsas R, Gasparro FP, Vowels BR. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol. 1996;107:235-242.
33. Tokura Y, Seo N, Yagi H, Takigawa M. Photoactivational cytokine-modulatory action of 8-methoxy psoralen plus ultraviolet A in lymphocytes, monocytes, and cutaneous T-cell lymphoma cells. Ann N Y Acad Sci. 2001;941:185-193.
34. Bergfelt L. UV-related skin conditions and Langerhans' cell populations in human skin. Acta Derm Venereol. 1993;73:194-196.
35. Berger CL, Hanlon D, Kanada D, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood. 2002;99:2929-2939.
36. Epstein EH Jr, Levin DL, Croft JD Jr, Lutzner MA. Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings. Medicine (Baltimore). 1972;51:61-72.
37. Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides. Arch Dermatol. 2003;139:165-173.
38. Jones GW, Wong R, Kastikainen J, et al. 15-year results of total skin electron beam (TSEB) radiation as first-line monotherapy for newly diagnosed stage IA-IB mycosis fungoides (MF). Int J Radiat Oncol Biol Phys. 2003;57:S291.
39. Vonderheid E, Tan E, Kantor A, et al. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma. J Am Acad Dermatol. 1989;20:416-428.
40. Kaye FJ, Bunn PA, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321:1784-1790.
41. Rosen ST, Foss FM. Chemotherapy for mycosis fungoides and the Sézary syndrome. Hematol Oncol Clin North Am. 1995;9:1109-1116.
42. Koh HK, Jacobson JO, Foss FM, Lew RA. Is cutaneous T-cell lymphoma curable? Arch Dermatol. 1995;131:1081-1082.